Axovant’s interpirdine fails to meet the trial’s primary endpoints. Read the Alzheimer’s Forum interpirdine report
What potential therapy reports out next? There are not a lot of large, late stage, Alzheimer’s trial results expected until 2019 (including Biogen’s aducanumab, Merck’s BACE- oriented verubecestat, and Lilly/AstraZeneca’s lanabecestat).